Corticosteroid therapy associated with COVID-19 : an ally or a risk factor for the establishment of secondary fungal co-infections?

Detalhes bibliográficos
Autor(a) principal: Amaral, Thaís Ferreira do
Data de Publicação: 2022
Outros Autores: Coutinho, Natália Monteiro da Silva Rodrigues, Fuentefria, Rubia do Nascimento, Fuentefria, Alexandre Meneghello, Machado, Gabriella da Rosa Monte
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRGS
Texto Completo: http://hdl.handle.net/10183/270831
Resumo: Corticosteroid therapy to combat inflammation caused by SARS-CoV-2 seems to be a risk factor for developing secondary fungal co-infections. PubMed and ScienceDirect databases were searched, with the following word groups: [(aspergillosis OR mucormycosis OR candidiasis) AND (coronavirus disease) AND (corticoids). The selected articles present the main risk factors related to the establishment of secondary fungal co-infections in COVID-19 patients. Corticosteroid therapy used to combat inflammation caused by SARS-CoV-2 has been shown to be strongly associated with the establishment of mucormycosis and aspergillosis. Mucormycosis has been the main fungal co-infection related to corticosteroid therapy, causing a high number of deaths in COVID-19 patients. Diabetes mellitus was the most prevalent comorbidity, especially for the establishment of mucormycosis. Dexamethasone use seems to be associated with mucormycosis emergence and death. However, aspergillosis showed a greater relationship with patient recovery. Thus, risk factors such as diabetes mellitus, combined with corticosteroid use, have shown a relationship to the establishment of mucormycosis. The corticosteroids used in COVID-19 patients should be individually analyzed, considering the patient’s medical history and the risk/benefit ratio of the use of these drugs.
id UFRGS-2_c6b03d77f990e5811abd7c90e2ddced2
oai_identifier_str oai:www.lume.ufrgs.br:10183/270831
network_acronym_str UFRGS-2
network_name_str Repositório Institucional da UFRGS
repository_id_str
spelling Amaral, Thaís Ferreira doCoutinho, Natália Monteiro da Silva RodriguesFuentefria, Rubia do NascimentoFuentefria, Alexandre MeneghelloMachado, Gabriella da Rosa Monte2024-01-11T03:25:20Z20222357-9730http://hdl.handle.net/10183/270831001193068Corticosteroid therapy to combat inflammation caused by SARS-CoV-2 seems to be a risk factor for developing secondary fungal co-infections. PubMed and ScienceDirect databases were searched, with the following word groups: [(aspergillosis OR mucormycosis OR candidiasis) AND (coronavirus disease) AND (corticoids). The selected articles present the main risk factors related to the establishment of secondary fungal co-infections in COVID-19 patients. Corticosteroid therapy used to combat inflammation caused by SARS-CoV-2 has been shown to be strongly associated with the establishment of mucormycosis and aspergillosis. Mucormycosis has been the main fungal co-infection related to corticosteroid therapy, causing a high number of deaths in COVID-19 patients. Diabetes mellitus was the most prevalent comorbidity, especially for the establishment of mucormycosis. Dexamethasone use seems to be associated with mucormycosis emergence and death. However, aspergillosis showed a greater relationship with patient recovery. Thus, risk factors such as diabetes mellitus, combined with corticosteroid use, have shown a relationship to the establishment of mucormycosis. The corticosteroids used in COVID-19 patients should be individually analyzed, considering the patient’s medical history and the risk/benefit ratio of the use of these drugs.application/pdfengClinical and biomedical research. Porto Alegre. Vol. 42, no. 4 (2022), p. 369-377CorticosteróidesEfeitos adversosCOVID-19Tratamento farmacológico da COVID-19AspergiloseCoinfecçãoMucormicoseFungal co-infectionsMucormycosisAspergillosisCorticotherapyCorticosteroid therapy associated with COVID-19 : an ally or a risk factor for the establishment of secondary fungal co-infections?info:eu-repo/semantics/articleinfo:eu-repo/semantics/otherinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001193068.pdf.txt001193068.pdf.txtExtracted Texttext/plain0http://www.lume.ufrgs.br/bitstream/10183/270831/2/001193068.pdf.txtd41d8cd98f00b204e9800998ecf8427eMD52ORIGINAL001193068.pdfTexto completo (inglês)application/pdf2060990http://www.lume.ufrgs.br/bitstream/10183/270831/1/001193068.pdf21d39d56927dc5cef8d87d65c461ff65MD5110183/2708312024-01-12 04:28:28.994286oai:www.lume.ufrgs.br:10183/270831Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2024-01-12T06:28:28Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.pt_BR.fl_str_mv Corticosteroid therapy associated with COVID-19 : an ally or a risk factor for the establishment of secondary fungal co-infections?
title Corticosteroid therapy associated with COVID-19 : an ally or a risk factor for the establishment of secondary fungal co-infections?
spellingShingle Corticosteroid therapy associated with COVID-19 : an ally or a risk factor for the establishment of secondary fungal co-infections?
Amaral, Thaís Ferreira do
Corticosteróides
Efeitos adversos
COVID-19
Tratamento farmacológico da COVID-19
Aspergilose
Coinfecção
Mucormicose
Fungal co-infections
Mucormycosis
Aspergillosis
Corticotherapy
title_short Corticosteroid therapy associated with COVID-19 : an ally or a risk factor for the establishment of secondary fungal co-infections?
title_full Corticosteroid therapy associated with COVID-19 : an ally or a risk factor for the establishment of secondary fungal co-infections?
title_fullStr Corticosteroid therapy associated with COVID-19 : an ally or a risk factor for the establishment of secondary fungal co-infections?
title_full_unstemmed Corticosteroid therapy associated with COVID-19 : an ally or a risk factor for the establishment of secondary fungal co-infections?
title_sort Corticosteroid therapy associated with COVID-19 : an ally or a risk factor for the establishment of secondary fungal co-infections?
author Amaral, Thaís Ferreira do
author_facet Amaral, Thaís Ferreira do
Coutinho, Natália Monteiro da Silva Rodrigues
Fuentefria, Rubia do Nascimento
Fuentefria, Alexandre Meneghello
Machado, Gabriella da Rosa Monte
author_role author
author2 Coutinho, Natália Monteiro da Silva Rodrigues
Fuentefria, Rubia do Nascimento
Fuentefria, Alexandre Meneghello
Machado, Gabriella da Rosa Monte
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Amaral, Thaís Ferreira do
Coutinho, Natália Monteiro da Silva Rodrigues
Fuentefria, Rubia do Nascimento
Fuentefria, Alexandre Meneghello
Machado, Gabriella da Rosa Monte
dc.subject.por.fl_str_mv Corticosteróides
Efeitos adversos
COVID-19
Tratamento farmacológico da COVID-19
Aspergilose
Coinfecção
Mucormicose
topic Corticosteróides
Efeitos adversos
COVID-19
Tratamento farmacológico da COVID-19
Aspergilose
Coinfecção
Mucormicose
Fungal co-infections
Mucormycosis
Aspergillosis
Corticotherapy
dc.subject.eng.fl_str_mv Fungal co-infections
Mucormycosis
Aspergillosis
Corticotherapy
description Corticosteroid therapy to combat inflammation caused by SARS-CoV-2 seems to be a risk factor for developing secondary fungal co-infections. PubMed and ScienceDirect databases were searched, with the following word groups: [(aspergillosis OR mucormycosis OR candidiasis) AND (coronavirus disease) AND (corticoids). The selected articles present the main risk factors related to the establishment of secondary fungal co-infections in COVID-19 patients. Corticosteroid therapy used to combat inflammation caused by SARS-CoV-2 has been shown to be strongly associated with the establishment of mucormycosis and aspergillosis. Mucormycosis has been the main fungal co-infection related to corticosteroid therapy, causing a high number of deaths in COVID-19 patients. Diabetes mellitus was the most prevalent comorbidity, especially for the establishment of mucormycosis. Dexamethasone use seems to be associated with mucormycosis emergence and death. However, aspergillosis showed a greater relationship with patient recovery. Thus, risk factors such as diabetes mellitus, combined with corticosteroid use, have shown a relationship to the establishment of mucormycosis. The corticosteroids used in COVID-19 patients should be individually analyzed, considering the patient’s medical history and the risk/benefit ratio of the use of these drugs.
publishDate 2022
dc.date.issued.fl_str_mv 2022
dc.date.accessioned.fl_str_mv 2024-01-11T03:25:20Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/other
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10183/270831
dc.identifier.issn.pt_BR.fl_str_mv 2357-9730
dc.identifier.nrb.pt_BR.fl_str_mv 001193068
identifier_str_mv 2357-9730
001193068
url http://hdl.handle.net/10183/270831
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv Clinical and biomedical research. Porto Alegre. Vol. 42, no. 4 (2022), p. 369-377
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRGS
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Repositório Institucional da UFRGS
collection Repositório Institucional da UFRGS
bitstream.url.fl_str_mv http://www.lume.ufrgs.br/bitstream/10183/270831/2/001193068.pdf.txt
http://www.lume.ufrgs.br/bitstream/10183/270831/1/001193068.pdf
bitstream.checksum.fl_str_mv d41d8cd98f00b204e9800998ecf8427e
21d39d56927dc5cef8d87d65c461ff65
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv
_version_ 1801225108591738880